Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg." He is currently an analyst with Aegis Capital Corp.
Ram Selvaraju: A Pair of Companies Ride the Sea Change in Cancer Therapeutics (2/4/14) A new generation of oncology treatments is moving through clinical trials toward the market. These proposed products are revolutionary in both their approaches to disease and their expected efficacy. Raghuram "Ram" Selvaraju, armed with his background as a drug developer, has followed dozens of highly innovative small- and mid-cap biotech companies, many of which he originally spotted as micro caps. In his second of three interviews with The Life Sciences Report, the head of equity healthcare research at Aegis Capital Corp. highlights two names with huge growth prospects.
Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector (12/5/13) An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers. Raghuram "Ram" Selvaraju, managing director and head of equity healthcare research at Aegis Capital, begs to differ. His research has uncovered small- and micro-cap companies developing sophisticated platforms in the molecular diagnostics space that are destined for significant revenue growth and profits. In his first of three interviews with The Life Sciences Report, Selvaraju lays out a handful of names with powerful technologies on the cusp of investor acceptance as huge growth plays.
Raghuram 'Ram' Selvaraju on the Best Biotech Ideas of 2013 (7/18/13) Small-cap, oncology-focused biotechs with novel technologies have always been bestsellers for investors. Subplots have emerged along the way, but Aegis Capital Corp.'s Managing Director and Head of Healthcare Equity Research Raghuram "Ram" Selvaraju maintains that these companies continue to drive the biotech story forward. In this interview with The Life Sciences Report, Selvaraju reflects on the state of the industry and shares reams of information on specific ideas for investors.
"We think that CGXI is an attractive investment at this juncture primarily because it has a diversified revenue model." (12/5/13) Cancer Genetics Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"We have raised our 12-month price target for CPRX to $6/share; the profile for CPP-115 keeps getting better and better." (11/25/13) Catalyst Pharmaceutical Partners Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"CUR closed Q2/13 with $11.2M in cash and equivalents, which we anticipate to be sufficient to fund operations well into 2014." (8/16/13) Neuralstem Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"Firdapse could generate $80ľ100M in sales every year for CPRX, which has a $40M market cap." (7/18/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"We continue to be positive on GALE's NeuVax, which is proposed to prevent recurrence of breast cancer in disease-free patients." (7/18/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"CUR is one of the best stories in the stem cell arena and it has a rich calendar of catalysts in 2013 and into H1/14." (7/18/13) Neuralstem Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"Animal data has indicated LPTN's ASONEP™ may have activity in renal cell carcinoma, including that which is resistant to currently marketed drugs." (3/14/13) Lpath Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>
"VPT's technology platform is very interesting and is fundamentally underrated and misunderstood by the market." (11/1/12) VentriPoint Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico Moreá>
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor Moreá>
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay Moreá>